Evidence map›Paper›PMID 30350272›Full record

ReviewBiological trace element research2019

Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.

Samuel Treviño, Alfonso Díaz, Eduardo Sánchez-Lara, Brenda L Sanchez-Gaytan, Jose Manuel Perez-Aguilar, Enrique González-Vergara

Open access · hybridAbstract readReview
In one paragraph

Review in Biological trace element research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 1 synthesis or guideline pooled it, 333 citations in OpenAlex.

  1. Evaluation of Fetal Exposures to Metals and Metalloids through Meconium Analyses: A Review.International journal of environmental research and public health · 2021
    Pooled it
  2. Vanadium salt inhibits osteoclast formation and preserves bone integrity in a rat model of type-1 diabetes associated bone loss.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  3. Vanadium(IV)-chlorodipicolinate alleviates hepatic steatosis via the AMPK/PGC-1α/CPT1a axis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Chronic exposure to low levels of glyphosate and metals induces kidney dysfunction.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  15. Does magnesium, one of the treatments for preeclampsia, interact with vanadium?Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Speciation and structural transformation of a VInorganic chemistry frontiers · 2025
    Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Samuel TreviñoFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico.
Alfonso DíazFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico.
Eduardo Sánchez-LaraCentro de Química, ICUAP, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico.
Brenda L Sanchez-GaytanCentro de Química, ICUAP, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico.
Jose Manuel Perez-AguilarFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico.
Enrique González-VergaraCentro de Química, ICUAP, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, C.P. 72570, Puebla, PUE, Mexico. enrique.gonzalez@correo.buap.mx.ORCID http://orcid.org/0000-0002-9883-4921
Benemérita Universidad Autónoma de Puebla · MX

Funding

Consejo Nacional de Ciencia y Tecnología 293256Vicerrectoria de Investigación y Estudios de Posgrado 100517029-VIEP2018Vicerrectoría de Investigación y Estudios de Posgrado 100256733-VIEP2018Vicerrectoría de Investigación y Estudios de Posgrado 100517029-VIEP2018
6 · The paper itself

Abstract

Vanadium compounds have been primarily investigated as potential therapeutic agents for the treatment of various major health issues, including cancer, atherosclerosis, and diabetes. The translation of vanadium-based compounds into clinical trials and ultimately into disease treatments remains hampered by the absence of a basic pharmacological and metabolic comprehension of such compounds. In this review, we examine the development of vanadium-containing compounds in biological systems regarding the role of the physiological environment, dosage, intracellular interactions, metabolic transformations, modulation of signaling pathways, toxicology, and transport and tissue distribution as well as therapeutic implications. From our point of view, the toxicological and pharmacological aspects in animal models and humans are not understood completely, and thus, we introduced them in a physiological environment and dosage context. Different transport proteins in blood plasma and mechanistic transport determinants are discussed. Furthermore, an overview of different vanadium species and the role of physiological factors (i.e., pH, redox conditions, concentration, and so on) are considered. Mechanistic specifications about different signaling pathways are discussed, particularly the phosphatases and kinases that are modulated dynamically by vanadium compounds because until now, the focus only has been on protein tyrosine phosphatase 1B as a vanadium target. Particular emphasis is laid on the therapeutic ability of vanadium-based compounds and their role for the treatment of diabetes mellitus, specifically on that of vanadate- and polioxovanadate-containing compounds. We aim at shedding light on the prevailing gaps between primary scientific data and information from animal models and human studies.

Indexed as

AnimalsDiabetes MellitusHumansHypoglycemic AgentsVanadiumVanadium CompoundsHypoglycemic AgentsVanadiumVanadium CompoundsBiological actionDiabetes mellitusMetabolic aspectsMetabolic implicationsMetallopharmaceuticalsVanadium

Identifiers

PMID30350272
PMCPMC6373340
OpenAlexW2895779069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.